Table 1 Clinical and baseline characteristics of the study 12-month brolucizumab cohort
12-month brolucizumab cohort | Baseline injection interval sub-groups | Baseline VA sub-groups (ETDRS letter range) | ||||||
|---|---|---|---|---|---|---|---|---|
Patients N = 154 | Eyes N = 174 | Injection intervals < 8 weeks n = 120 eyes | Injection intervals ≥ 8 weeks n = 54 eyes | Quartile 1 (74.2, 85.0) n = 43 eyes | Quartile 2 (65.1, 74.2) n = 40 eyes | Quartile 3 (53.9, 65.1) n = 48 eyes | Quartile 4 (19.9, 53.9) n = 43 eyes | |
Age, years (Mean, [SD]) | 80.5 (7.7) | – | 80.8 (7.6) | 80.7 (8.6) | 78.3 (9.0) | 80.4 (7.0) | 81.6 (7.5) | 82.5 (7.5) |
Gender | ||||||||
Female: N, % | 86 (55.8) | – | 73 (60.8) | 25 (46.3) | 27 (62.8) | 23 (57.5) | 26 (54.2) | 22 (51.2) |
Male: N, % | 67 (43.5) | – | 46 (38.3) | 29 (53.7) | 15 (34.9) | 17 (42.5) | 22 (45.8) | 21 (48.8) |
Time from nAMD diagnosis to first brolucizumab (mean months [SD]) | – | 47.7 (35.5) | – | – | – | – | – | – |
Time from first anti-VEGF to first brolucizumab (mean months [SD]) | – | 39.0 (33.3) | – | – | – | – | – | – |
VA (ETDRS letters; mean [SD]) | – | 60.8 (17.1) | 61.9 (16.3) | 58.5 (18.7) | 78.9 (3.3) | 69.4 (2.5) | 60.3 (3.6) | 35.4 (10.2) |
Injection interval (mean days [SD]) | – | 47.8 (25.1) | 36.6 (7.7) | 72.8 (31.6) | 43.9 (14.2) | 50.8 (34.1) | 48.9 (28.5) | 47.7 (19.5) |
Follow up period from first brolucizumab injection (mean days [SD]) | – | 562.8 (104.8) | 571.9 (107.6) | 542.7 (96.3) | 612.1 (86.3) | 569.1 (113.3) | 544.6 (96.7) | 528.1 (106.1) |
CMT (N [%]) | – | 162 (93.1) | 115 (95.8) | 47 (87.0) | 42 (97.7) | 35 (87.5) | 45 (93.8) | 40 (93.0) |
CMT, µm (Mean [SD]) | – | 292.2 (113.3) | 294.8 (111.6) | 285.8 (118.4) | 265.8 (74.6) | 287.3 (66.9) | 280.0 (70.1) | 338.0 (186.0) |
IRF (n [%]) | – | 40 (23.0) | 23 (19.2) | 17 (31.5) | 5 (11.6) | 6 (15.0) | 12 (25.0) | 17 (39.5) |
SRF (n [%]) | – | 102 (58.6) | 68 (56.7) | 34 (63.0) | 23 (53.5) | 23 (57.5) | 31 (64.6) | 25 (58.1) |
PED (n [%]) | – | 109 (62.6) | 75 (62.5) | 34 (63.0) | 18 (41.9) | 25 (62.5) | 37 (77.1) | 29 (67.4) |